Announcing: CancerIQ for Preventive Care
CancerIQ is enabling primary care providers to assess every patient’s comprehensive cancer risk and navigate them through hyper-personalized cancer prevention pathways. We're expanding beyond hereditary cancers to reduce risk across all types of cancer, allowing health systems to realize the clinical and financial benefits of risk-based cancer screening at the population level.
Improving outcomes at the population level
Each person’s cancer risk is based on a unique combination of factors, including family history, lifestyle choices and screening adherence. But the current healthcare system relies on a one-size-fits-all, age-driven approach to cancer screening and prevention — meaning many patients receive late-stage diagnoses that could have been detected earlier or avoided altogether.
“Every patient who walks through the door deserves a personalized, evidence-based action plan to ensure they get the right care, at the right time, to reduce their cancer risk. And primary care providers deserve to have a platform that enables them to make that a reality.”
Live at HLTH on The Newsroom Stage
CancerIQ CEO invites health systems to join 7 others in national PREVENT initiative to measure the impact of risk-based cancer screening at scale
The expanded platform
Personalized risk assessments
Our expanded platform conducts personalized risk assessments using patient-collected data, EHR data, & the latest risk models and oncology guidelines.
The platform’s risk stratification and recommendation engine make it easy for primary care providers to segment all patients by risk level across the population.
Automated documentation and test ordering tools are built directly into the workflow to streamline and guide shared decision making and patient activation at the point of care.
Engage and educate patients, and generate care plan recommendations with included patient letters.
Initial clinical findings
An initial implementation of CancerIQ’s expanded platform at three health systems found clinical and financial benefits. Of assessed patients, the platform identified 36% needed hereditary cancer testing, 5% needed a low-dose lung CT, and 16% needed a colonoscopy. Without CancerIQ, these patients may have missed out on these tests that can help prevent a late-stage cancer diagnosis.
36% OF PATIENTS
needed hereditary cancer screening
5% OF PATIENTS
needed low-dose lung CT screening
16% OF PATIENTS
needed colorectal cancer screening
At HLTH, CancerIQ extended the invitation to forward-thinking hospitals and health systems that want to reduce cancer risk and improve outcomes at the population level.
CancerIQ is conducting the PREVENT initiative to continue to measure the clinical and financial impact of its expanded platform across more diverse clinical settings. PREVENT stands for patient risk evaluation, education, navigation and testing). Seven health systems from across the country, serving urban and rural patient populations, have already signed on to participate.